- Home
- EAD vs XFOR Comparison
EAD vs XFOR Comparison
Compare EAD & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | XFOR |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.3M | 407.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EAD | XFOR |
|---|---|---|
| Price | $6.52 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 145.0K | ★ 342.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.24 | $1.35 |
| 52 Week High | $7.18 | $4.83 |
Technical Indicators
Market Signals| Indicator | EAD | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 49.45 |
| Support Level | $6.24 | $3.97 |
| Resistance Level | $6.73 | $4.09 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 44.44 | 48.08 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.